• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Lucid Diagnostics Inc.

    1/31/25 4:46:39 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care
    Get the next $LUCD alert in real time by email
    S-8 1 forms-8.htm

     

    As filed with the Securities and Exchange Commission on January 31, 2025

     

    Registration No. 333-

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    LUCID DIAGNOSTICS INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   82-5488042
    (State or other jurisdiction of   (I.R.S. Employer
    incorporation or organization)   Identification No.)

     

    360 Madison Avenue, 25th Floor

    New York, NY 10017

    (Address of Principal Executive Offices) (Zip Code)

     

    LUCID DIAGNOSTICS INC. AMENDED AND RESTATED 2018 LONG TERM INCENTIVE PLAN

    (Full title of the plan)

     

    Dr. Lishan Aklog, Chairman and Chief Executive Officer

    Lucid Diagnostics Inc.

    360 Madison Avenue, 25th Floor

    New York, NY 10017

    (Name and address of agent for service)

     

    (917) 813-1828

    (Telephone number, including area code, of agent for service)

     

    with a copy to:

     

    David Alan Miller, Esq.

    Eric T. Schwartz, Esq.

    Graubard Miller

    The Chrysler Building

    405 Lexington Avenue, 44th floor

    New York, NY 10174

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

      Large accelerated filer ☐   Accelerated filer ☐
      Non-accelerated filer ☒   Smaller reporting company ☒
          Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    In accordance with the provisions of Rule 462 promulgated under the Securities Act of 1933, as amended, the Registration Statement will become effective upon filing with the Securities and Exchange Commission.

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This registration statement is filed by Lucid Diagnostics Inc. (the “Company”) to register an additional 4,018,163 shares of the Company’s common stock issuable pursuant to the Company’s Amended and Restated 2018 Long-Term Incentive Equity Plan (the “Plan”), consisting of additional securities in accordance with Section 3.1 of the Plan, and consists of only those items required by General Instruction E to Form S-8. The Company hereby incorporates by reference into this registration statement the contents of the prior registration statement on Form S-8 relating to the Plan, filed with the Securities and Exchange Commission (the “SEC”) on December 21, 2021 (File No. 333-261807), February 10, 2023 (File No. 333-269702) and February 6, 2024 (File No. 333-276908).

     

     

     

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1. Plan Information.*

     

    Item 2. Registrant Information and Employee Plan Annual Information.*

     

    * The information required by this Part I is omitted from this Registration Statement in accordance with rules and regulations under the Securities Act of 1933, as amended (“Securities Act”), and the Note to Part I of Form S-8. The documents containing the information specified in this Part I will be sent or given to employees, officers, directors or others as specified by Rule 428(b)(1) under the Securities Act. Such documents and the documents incorporated by reference herein pursuant to Item 3 of Part II of this registration statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

     

     

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents that we have previously filed with the SEC are incorporated by reference in this registration statement (excluding any reports or portions thereof that are furnished under Item 2.02 or Item 7.01 and any exhibits included with such items):

     

      ● The Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (filed on March 25, 2024).
         
      ● The quarterly reports on Form 10-Q for each of the period ended March 31, 2024 (filed on May 13, 2024), the period ended June 30, 2024 (filed on August 12, 2024), and the period ended September 30, 2024 (filed on November 12, 2024).
         
      ● The current reports on Form 8-K dated January 26, 2024 (filed on January 30, 2024), March 13, 2024 (filed on March 14, 2024), May 1, 2024 (filed on May 7, 2024), May 24, 2024 (filed on May 24, 2024), June 21, 2024 (filed on June 21, 2024), July 23, 2024 (filed on July 24, 2024), November 8, 2024 (filed on November 12, 2024), November 12, 2024 (filed on November 18, 2024), November 22, 2024 (filed on November 29, 2024) and December 19, 2024 (filed on December 20, 2024).
         
      ● The description of our common stock in the Form 8-A dated October 12, 2021, including any amendment or report filed under the Exchange Act for the purpose of updating such description, including Exhibit 4.1 to our annual report on Form 10-K for the fiscal year ended December 31, 2023.

     

    All documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), prior to the filing of a post-effective amendment which indicates that all the securities offered have been sold or which deregisters all securities then remaining unsold (excluding any reports or portions thereof that are furnished under Item 2.02 or Item 7.01 of a Current Report on Form 8-K and any exhibits included with such items) will be deemed to be incorporated by reference in this registration statement and to be a part of this registration statement from the respective date of filing.

     

    Any statement contained herein or in a document incorporated by reference herein will be modified or superseded for all purposes to the extent that a statement contained herein or in any other subsequently filed document which is incorporated by reference herein modifies or replaces the statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this registration statement.

     

    Notwithstanding the foregoing, we are not incorporating any document or portion thereof or information deemed to have been furnished and not filed in accordance with SEC rule.

     

    Item 5. Interests of Named Experts and Counsel.

     

    Graubard Miller issued the opinion as to the legality of the shares of our common stock being registered pursuant to this registration statement.

     

    Item 8. Exhibits.

     

    See the Exhibit Index, which is incorporated herein by reference.

     

    Item 9. Undertakings.

     

    (a) The undersigned Registrant hereby undertakes:

     

      (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:

     

      (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

     

     

     

     

      (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement;
         
      (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement.

     

    Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in this registration statement.

     

      (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
         
      (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (h) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing procedures, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in New York, New York on this 31st day of January, 2025.

     

      LUCID DIAGNOSTICS INC.
         
      By: /s/ Lishan Aklog, M.D.
        Lishan Aklog, M.D.
        Chairman and Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Lishan Aklog, M.D. and Dennis M. McGrath, and each of them, with full power to act without the other, such person’s true and lawful attorneys-in-fact and agents, with full power of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities, to sign this registration statement, any and all amendments thereto (including post-effective amendments), and any amendments thereto and to file the same, with exhibits and schedules thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing necessary or desirable to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signatures   Title   Date
               
    By: /s/ Lishan Aklog, M.D.   Chairman and Chief Executive Officer   January 31, 2025
      Lishan Aklog, M.D.   (Principal Executive Officer)    
               
    By: /s/ Dennis M. McGrath   Chief Financial Officer (Principal   January 31, 2025
      Dennis M. McGrath   Financial and Accounting Officer)    
               
    By: /s/ Stanley N. Lapidus   Vice Chairman and Director   January 31, 2025
      Stanley N. Lapidus        
               
    By: /s/ James L. Cox, M.D.   Director   January 31, 2025
      James L. Cox, M.D.        
               
    By: /s/ Dennis A. Matheis   Director   January 31, 2025
      Dennis A. Matheis        
               
    By: /s/ Jacque J. Sokolov, M.D.   Director   January 31, 2025
      Jacque J. Sokolov, M.D.        
               
    By: /s/ Ronald M. Sparks   Director   January 31, 2025
      Ronald M. Sparks        
               
    By: /s/ Debra J. White   Director   January 31, 2025
      Debra J. White        

     

     

     

     

    EXHIBIT INDEX

     

            Incorporated by Reference    
    Exhibit No.   Description   Form   Filing Date   Exhibit No.   Filed Herewith
    3.1   Amended and Restated Certificate of Incorporation   S-1/A   10/7/21   3.1    
    3.2   Certificate of Amendment to Certificate of Incorporation, dated June 21, 2023   8-K   6/21/23   3.1    
    3.3   Certificate of Amendment to Certificate of Incorporation, dated July 23, 2024   8-K   7/23/24   3.1    
    3.4   Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock   8-K   3/14/24   3.1    
    3.5   Certificate of Designation of Preferences, Rights and Limitations of Series B-1 Convertible Preferred Stock   8-K   5/7/24   3.1    
    3.6   Amended and Restated Bylaws   S-1/A   10/7/21   3.2    
    4.1   Specimen Lucid Diagnostics Inc. Common Stock Certificate   S-1/A   10/7/21   4.1    
    5.1   Opinion of Graubard Miller               X
    10.1   Lucid Diagnostics Inc. Amended and Restated 2018 Long-Term Incentive Equity Plan   14A   5/2/22   Annex A    
    23.1   Consent of Marcum LLP               X
    23.2   Consent of Graubard Miller (included in Exhibit 5.1)               X
    24.1   Power of Attorney (included on the signature page hereto)               X
    107   Fee Calculation Table               X

     

     

     

    Get the next $LUCD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LUCD

    DatePrice TargetRatingAnalyst
    12/27/2021$16.00Buy
    Ascendiant Capital
    12/15/2021$17.00 → $13.00Buy
    Needham
    11/8/2021$18.00Buy
    Canaccord Genuity
    11/8/2021$14.00Buy
    BTIG Research
    11/8/2021$21.00Overweight
    Cantor Fitzgerald
    11/8/2021$17.00Buy
    Needham
    More analyst ratings

    $LUCD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Matheis Dennis bought $101,840 worth of shares (100,000 units at $1.02), increasing direct ownership by 18% to 665,443 units (SEC Form 4)

    4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

    8/22/25 5:17:58 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Amendment: Director Matheis Dennis bought $457,607 worth of shares (350,000 units at $1.31), increasing direct ownership by 40% to 565,443 units (SEC Form 4)

    4/A - Lucid Diagnostics Inc. (0001799011) (Issuer)

    5/23/25 4:14:42 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Director Matheis Dennis bought $457,607 worth of shares (350,000 units at $1.31) (SEC Form 4)

    4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

    5/22/25 4:45:49 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    $LUCD
    SEC Filings

    View All

    SEC Form S-3 filed by Lucid Diagnostics Inc.

    S-3 - Lucid Diagnostics Inc. (0001799011) (Filer)

    12/5/25 5:01:46 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Lucid Diagnostics Inc. (0001799011) (Filer)

    11/12/25 8:15:37 AM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Lucid Diagnostics Inc.

    10-Q - Lucid Diagnostics Inc. (0001799011) (Filer)

    11/12/25 8:01:13 AM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    $LUCD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Palumbo John R

    4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

    10/7/25 4:46:05 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    New insider Palumbo John R claimed ownership of 47,857 shares (SEC Form 3)

    3 - Lucid Diagnostics Inc. (0001799011) (Issuer)

    10/7/25 4:45:33 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Director Matheis Dennis bought $101,840 worth of shares (100,000 units at $1.02), increasing direct ownership by 18% to 665,443 units (SEC Form 4)

    4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

    8/22/25 5:17:58 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    $LUCD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities

    Series D Preferred Stock offering yielded $30 million of gross proceeds and includes warrants exercisable for up to an additional $30 million upon publication of a positive draft EsoGuard Medicare local coverage determination Series D Preferred Stock convertible into common stock subject to stockholder approval at an upcoming special meeting New senior secured note with three-year maturity yielded an additional $15 million of gross proceeds Proceeds used to redeem and retire all previously outstanding convertible securities, eliminating a significant legacy capital structure overhang Transactions yielded approximately $7.7 million in net cash proceeds, materially strengthening the Company's

    2/4/26 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®

    NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it has been awarded a contract by the U.S. Department of Veterans Affairs (VA) for its EsoGuard® Esophageal DNA Test, expanding access to esophageal precancer testing across the nation's largest integrated healthcare system, which serves more than nine million enrolled veterans annually. The contract is issued under the VA Federal Supply Schedu

    1/21/26 8:00:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    PAVmed Announces Reverse Stock Split

    NEW YORK, Dec. 30, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced it will conduct a 1-for-30 reverse stock split of its common stock (the "Common Stock"). The reverse stock split will become effective on January 2, 2026, at 12:01 a.m. Eastern Time. The Company's Common Stock will continue to trade on the Nasdaq Capital Market ("Nasdaq") under the symbol "PAVM" and will begin trading on a split-adjusted basis at the opening of the market on January 2, 2026. The reverse stock split is intended to bring the Company into

    12/30/25 9:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $LUCD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ascendiant Capital initiated coverage on Lucid Diagnostics with a new price target

    Ascendiant Capital initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $16.00

    12/27/21 6:21:16 AM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Needham reiterated coverage on Lucid Diagnostics with a new price target

    Needham reiterated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $13.00 from $17.00 previously

    12/15/21 6:36:10 AM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Canaccord Genuity initiated coverage on Lucid Diagnostics with a new price target

    Canaccord Genuity initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $18.00

    11/8/21 10:16:23 AM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    $LUCD
    Financials

    Live finance-specific insights

    View All

    PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025

    Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, Oct. 30, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, November 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's thi

    10/30/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025

    Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, Oct. 29, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, November 12, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's third quarter 2025 f

    10/29/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

    Conference call scheduled for Monday, September 8, at 8:30 AM ET to discuss September 4 MolDX Contractor Advisory Committee (CAC) meeting NEW YORK, Sept. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today announced it will host a conference call on Monday, September 8, 2025, at 8:30 a.m. Eastern Time to discuss the September 4 Contractor Advisory Committee ("CAC") Meeting convened by MolDX-participating Medicare Administrative Contractors as part of the reconsideration of Local Coverage Determination (LCD) L39256, "MolDX: Molec

    9/5/25 9:16:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $LUCD
    Leadership Updates

    Live Leadership Updates

    View All

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs

    Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage expansion NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the appointment of Danielle Scelfo as Senior Vice President, Market Access & Government Affairs, reporting to the Chief Executive Officer. Ms. Scelfo is widely recognized in the diagnostics industry as an accomplished health policy leader with more than 25 years o

    9/16/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

    NEW YORK, May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Lucid is joining these importa

    5/27/25 7:31:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $LUCD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lucid Diagnostics Inc.

    SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)

    12/12/24 4:30:32 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lucid Diagnostics Inc.

    SC 13G/A - Lucid Diagnostics Inc. (0001799011) (Subject)

    7/8/24 3:49:29 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Lucid Diagnostics Inc. (Amendment)

    SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)

    2/20/24 4:45:37 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care